Two multicenter studies reinforced circulating tumor DNA’s clinical utility. Fox Chase Cancer Center’s phase 2 RETAIN‑2 trial showed that a ctDNA blood test identified muscle‑invasive bladder cancer patients with low metastatic risk who could potentially avoid immediate cystectomy. Separately, a Nature Communications multicenter study found tumor‑informed ctDNA outperformed tissue testing for matching patients to FGFR‑targeted therapies in metastatic urothelial cancer. Both reports support broader adoption of ctDNA to personalize treatment decisions and de‑risk surgical and systemic strategies.